NG-350A Plus Chemoradiotherapy for Locally Advanced Rectal Cancer
- Conditions
- Locally Advanced Rectal Cancer (LARC)
- Interventions
- First Posted Date
- 2024-06-14
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Akamis Bio
- Target Recruit Count
- 30
- Registration Number
- NCT06459869
- Locations
- 🇺🇸
The University of Texas MD Anderson Cnacer Center, Houston, Texas, United States
🇺🇸University of California Los Angeles (UCLA), Santa Monica, California, United States
🇺🇸Ohio State University Comprehensive Cancer Center (OSU), Columbus, Ohio, United States
Study of NG-350A Plus Pembrolizumab in Metastatic or Advanced Epithelial Tumours (FORTIFY)
- Conditions
- Epithelial TumorMetastatic Cancer
- Interventions
- Biological: NG-350A plus Pembrolizumab
- First Posted Date
- 2021-12-21
- Last Posted Date
- 2025-03-14
- Lead Sponsor
- Akamis Bio
- Target Recruit Count
- 198
- Registration Number
- NCT05165433
- Locations
- 🇬🇧
The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool, Lancashire, United Kingdom
🇺🇸Moffitt-Advent Health Clinical Research Unit, Celebration, Florida, United States
🇬🇧Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, Oxfordshire, United Kingdom
Study of NG-641 in Combination With Nivolumab in Metastatic or Advanced Epithelial Tumours
- Conditions
- Metastatic CancerEpithelial Tumor
- Interventions
- Biological: NG-641 in combination with Nivolumab
- First Posted Date
- 2021-09-14
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- Akamis Bio
- Target Recruit Count
- 30
- Registration Number
- NCT05043714
- Locations
- 🇺🇸
University of Cincinnati Cancer Center, Cincinnati, Ohio, United States
🇬🇧Oxford University Hospitals NHS Foundation Trust, Oxford, Oxfordshire, United Kingdom
🇬🇧The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool, Lancashire, United Kingdom
A Study of NG-641 and Pembrolizumab in Squamous Cell Carcinoma of the Head and Neck
- Conditions
- Squamous Cell Carcinoma of the Head and Neck
- Interventions
- First Posted Date
- 2021-04-05
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- Akamis Bio
- Target Recruit Count
- 36
- Registration Number
- NCT04830592
- Locations
- 🇬🇧
The Clatterbridge Cancer Centre, Liverpool, United Kingdom
🇬🇧The Royal Marsden Hospital, London, United Kingdom
🇬🇧Cardiff & Vale University LHB, Cardiff, United Kingdom
First in Human Study With NG-641, a Tumour Selective Transgene Expressing Adenoviral Vector
- First Posted Date
- 2019-08-12
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- Akamis Bio
- Target Recruit Count
- 186
- Registration Number
- NCT04053283
- Locations
- 🇺🇸
UCLA, Santa Barbara, California, United States
🇺🇸MD Anderson, Houston, Texas, United States
🇺🇸Moffitt-Advent Health Clinical Research Unit, Celebration, Florida, United States
First in Human Study of NG-350A (an Oncolytic Adenoviral Vector Which Expresses an Anti-CD40 Antibody)
- Conditions
- Epithelial TumorMetastatic Cancer
- Interventions
- Biological: NG-350A
- First Posted Date
- 2019-02-25
- Last Posted Date
- 2022-06-24
- Lead Sponsor
- Akamis Bio
- Target Recruit Count
- 28
- Registration Number
- NCT03852511
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center (MSKCC), New York, New York, United States
🇺🇸The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸University of California, Los Angeles (UCLA), Santa Monica, California, United States
Phase I Study of Enadenotucirev and PD-1 Inhibitor in Subjects With Metastatic or Advanced Epithelial Tumors
- Conditions
- Colorectal CancerSquamous Cell Carcinoma of the Head and NeckEpithelial Tumor
- Interventions
- Biological: enadenotucirevBiological: nivolumab
- First Posted Date
- 2015-12-21
- Last Posted Date
- 2021-11-09
- Lead Sponsor
- Akamis Bio
- Target Recruit Count
- 51
- Registration Number
- NCT02636036
- Locations
- 🇺🇸
UCLA Medical Center, 10945 Le Conte Ave, Ste. 3360, Santa Monica, California, United States
🇺🇸University of Arizona Cancer Center, 1515 North Campbell Ave., Tucson, Arizona, United States
🇺🇸Henry Ford Hospital, 2799 West Grand Blvd., Detroit, Michigan, United States
Mechanism of Action Trial of ColoAd1
- Conditions
- Resectable Bladder CancerResectable Renal Cell CarcinomaResectable Colon CancerResectable Non-small Cell Lung Cancer
- Interventions
- Biological: Colo-Ad1
- First Posted Date
- 2014-02-03
- Last Posted Date
- 2020-03-12
- Lead Sponsor
- Akamis Bio
- Target Recruit Count
- 17
- Registration Number
- NCT02053220
- Locations
- 🇪🇸
Hospital Universitario Virgen del RocÃo, Seville, Spain
🇪🇸Hospital Universitario Madrid Sanchinarro CIOCC, Madrid, Spain
Phase I / II Study of Enadenotucirev by Sub-acute Fractionated IV Dosing in Cancer Patients
- Conditions
- Solid Tumours of Epithelial OriginMetastatic Bladder CancerMetastatic Colorectal Cancer
- Interventions
- Biological: Enadenotucirev
- First Posted Date
- 2014-01-07
- Last Posted Date
- 2020-03-12
- Lead Sponsor
- Akamis Bio
- Target Recruit Count
- 61
- Registration Number
- NCT02028442
- Locations
- 🇧🇪
GZA ziekenhuizen campus Sint-Augustinus, Wilrijk, Antwerp, Belgium
🇧🇪Cliniques Universitaires St Luc, Bruxelles, Belgium
🇧🇪Ghent University Hospital, Ghent, Belgium
Phase I / Dose Expansion Study of Enadenotucirev in Ovarian Cancer Patients
- Conditions
- Recurrent Platinum Resistant Ovarian Cancer
- Interventions
- Biological: Enadenotucirev
- First Posted Date
- 2014-01-06
- Last Posted Date
- 2021-05-13
- Lead Sponsor
- Akamis Bio
- Target Recruit Count
- 38
- Registration Number
- NCT02028117
- Locations
- 🇪🇸
MD Anderson Cancer Center, Madrid, Spain
🇪🇸Hospital Universitari de Girona Dr. Josep Trueta, Girona, Spain
🇪🇸Clara Campal Comprehensive Cancer Center Hospital, Madrid, Spain